AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 143 min read$SKYE

Skye Bioscience, Redx Pharma To Combine To Operate As Fibrx Therapeutics

Skye Bioscience (SKYE) and privately held Redx Pharma agreed to combine and form Fibrx Therapeutics, expected to trade on Nasdaq. The deal is slated to close in Q4 2026, led by Redx management. About $125M financing is planned. Lead asset RXC008 targets fibrotic Crohn’s, with Phase 2 topline expected H2 2028. SKYE trades at $0.54.

Original reporting
rttnews.com
Published Aug 14, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 4:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$SKYE
Bullish
medium confidence
Mentioned
$SKYE
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$SKYEBullishMed
01

Why it matters

The definitive nature of the transaction plus disclosed PIPE and equity financing are likely to drive deal-spread trading and re-rating of SKYE, while the pipeline details set expectations for future clinical milestones.

02

Market read

Traders may focus on deal probability, financing structure, and how the newco’s fibrosis pipeline (RXC008, DDR inhibitor, RXC007) changes the risk profile for SKYE.

03

What to watch

The article omits key deal economics (consideration/valuation, exchange ratio, redemption terms) and does not specify whether SKYE’s current assets are retained or spun into the newco.

Relevance 8/10Novelty 7/10Timing: definitive deal announced, expected close in Q4 2026

Background

Skye Bioscience and privately held Redx Pharma announced a definitive agreement to combine and create Fibrx Therapeutics, a fibrosis-focused company.

Company-level read

Ticker impact

$SKYEBullishMedium confidence
Context

Skye Bioscience agreed to combine with Redx Pharma to form Fibrx Therapeutics, with closing expected in Q4 2026.

Expected impact

Near-term trading likely reflects deal spread and financing overhang, with direction dependent on perceived probability of closing.

Evidence & confidence

The article discloses a definitive transaction, ownership split, and $125M financing, which typically drives re-rating and spread trading, but lacks valuation/consideration details.

Market effects

Sector

Signals continued capital formation and consolidation in fibrosis-focused biotech, potentially improving sentiment for ROCK inhibitor and GI-restricted Crohn’s programs.

Regional

Primarily US biotech sentiment via expected Nasdaq listing, with limited direct regional spillover described.

Global

Limited global read-through in the article; focus is on US regulatory path (IND, Fast Track) and US listing.

Counterpoint

What could challenge this read

The financing and ownership split may not fully offset dilution and long clinical timelines, so the deal could underwhelm versus standalone value.

Key entities

  • company
    Skye Bioscience, Inc.

    US-listed biotech (SKYE) entering a definitive combination to form Fibrx Therapeutics.

  • company
    Redx Pharma

    Privately held biotech providing management leadership and contributing pipeline programs to the newco.

  • company
    Fibrx Therapeutics

    Expected Nasdaq-traded fibrosis-focused company formed from the Skye-Redx combination.

  • person
    Lisa Anson

    Named CEO of the combined company.

  • person
    Peter Collum

    Named CFO of the combined company.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 17
$SKYEMedAI 8/10

Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up

Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.

rttnews.com4 min
AUG 14
$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

finanznachrichten.de4 min
SEP 11
$KULRMed

KULR Technology Group, Inc. (KULR): Completion of Acquisition or Disposition of Assets

KULR Technology Group, Inc. (KULR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets During the period from August 20, 2026 through September 11, 2026, KULR Technology Group, Inc. (“KULR” or the “Company”) sold an aggregate of approximately 764 bitcoin (“BTC”) through a series of open market transaction

SEC EDGAR 8-K2 min
SEP 11
$SOARHigh

Volato Group, Inc. (SOAR): Completion of Acquisition or Disposition of Assets

Volato Group, Inc. (SOAR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry Into a Material Definitive Agreement. Merger Agreement Amendment As previously disclosed, on August 25, 2026, Volato Group, Inc., a Delaware corporation (“Volato” or the “Company”), entered into an Agreement and Plan of Merger (as subsequently amended, the “Merger

SEC EDGAR 8-K2 min
SEP 11
$AIBMed

AIB Data Centers Inc. (AIB): Completion of Acquisition or Disposition of Assets

AIB Data Centers Inc. (AIB) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 — Entry into a Material Definitive Agreement. On September 4, 2026, AIB Data Centers Inc. (the “Company”) entered into two interdependent definitive agreements to acquire certain real property and related assets located in Texas, comprising approximately 29.385 acres fo

SEC EDGAR 8-K1 min